Research Analysts Issue Forecasts for MNMD Q1 Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of Mind Medicine (MindMed) in a research report issued on Wednesday, May 21st. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of ($0.38) for the quarter. HC Wainwright currently has a "Buy" rating and a $55.00 price objective on the stock. The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Mind Medicine (MindMed)'s Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.36) EPS and FY2029 earnings at $2.87 EPS.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.01.

MNMD has been the subject of a number of other reports. Evercore ISI began coverage on Mind Medicine (MindMed) in a research report on Tuesday, January 28th. They issued an "outperform" rating and a $23.00 price target for the company. Cantor Fitzgerald upgraded shares of Mind Medicine (MindMed) to a "strong-buy" rating in a research report on Tuesday, May 13th. Chardan Capital restated a "buy" rating and issued a $20.00 target price on shares of Mind Medicine (MindMed) in a report on Friday, May 9th. Finally, Robert W. Baird dropped their price target on shares of Mind Medicine (MindMed) from $27.00 to $16.00 and set an "outperform" rating for the company in a research note on Friday, March 7th. Nine equities research analysts have rated the stock with a buy rating and four have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $25.11.

Mind Medicine (MindMed) Trading Up 0.8%

Shares of Mind Medicine (MindMed) stock traded up $0.06 on Friday, reaching $7.20. The company had a trading volume of 495,666 shares, compared to its average volume of 1,391,534. The firm has a market cap of $542.65 million, a price-to-earnings ratio of -3.19 and a beta of 2.52. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00. The firm's 50-day moving average price is $6.22 and its two-hundred day moving average price is $6.97. Mind Medicine has a 1 year low of $4.70 and a 1 year high of $10.44.

Institutional Trading of Mind Medicine (MindMed)

Several institutional investors and hedge funds have recently made changes to their positions in MNMD. Corebridge Financial Inc. increased its position in Mind Medicine (MindMed) by 4.1% during the 4th quarter. Corebridge Financial Inc. now owns 40,064 shares of the company's stock valued at $279,000 after purchasing an additional 1,569 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Mind Medicine (MindMed) by 6.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,867 shares of the company's stock valued at $169,000 after purchasing an additional 1,669 shares in the last quarter. Commonwealth Equity Services LLC increased its holdings in Mind Medicine (MindMed) by 9.9% during the fourth quarter. Commonwealth Equity Services LLC now owns 21,492 shares of the company's stock valued at $150,000 after buying an additional 1,928 shares during the period. Woodline Partners LP raised its stake in Mind Medicine (MindMed) by 0.3% in the fourth quarter. Woodline Partners LP now owns 1,005,198 shares of the company's stock worth $6,996,000 after buying an additional 2,654 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Mind Medicine (MindMed) by 8.2% in the third quarter. JPMorgan Chase & Co. now owns 36,995 shares of the company's stock worth $211,000 after purchasing an additional 2,797 shares in the last quarter. 27.91% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Daniel Karlin sold 6,836 shares of the stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total value of $46,074.64. Following the transaction, the insider now owns 446,177 shares of the company's stock, valued at $3,007,232.98. This represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert Barrow sold 21,208 shares of the firm's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total value of $142,941.92. Following the transaction, the chief executive officer now owns 856,556 shares in the company, valued at $5,773,187.44. The trade was a 2.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,391 shares of company stock valued at $204,835 in the last 90 days. Company insiders own 2.45% of the company's stock.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.